Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Yusuf
dc.contributor.authorOzturk, Oguzhan
dc.contributor.authorAlandab, Yesim Ozen
dc.contributor.authorSenates, Ebubekir
dc.contributor.authorColak, Yasar
dc.contributor.authorDoganay, Hamdi Levent
dc.contributor.authorCoskunpinar, Ender
dc.date.accessioned2024-04-24T16:11:16Z
dc.date.available2024-04-24T16:11:16Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Osteopontin is a secreted phosphorylated glycoprotein that is expressed by a variety of cell types and that mediates numerous and diverse biological functions. Osteopontin knockout mice are protected from obesity-induced hepatic steatosis. In the present study, we sought to investigate whether serum osteopontin concentrations are associated with liver histology in patients with nonalcoholic fatty liver disease. Methods: Serum levels of osteopontin were measured by enzyme-linked immunosorbent assay in 179 Well-characterized patients with nonalcoholic fatty liver referred for liver histology and 123 control subjects. Results: Serum osteopontin levels were markedly higher in patients with nonalcoholic fatty liver disease than in controls (p < 0.001). Multivariable analysis showed that osteopontin levels were strongly and independently associated with both portal inflammation (beta = 0.294, p < 0.01) and serum aminotransferase levels (aspartate aminotransferase: beta = 0.295, p < 0.01; alanine aminotransferase; beta = 0.285, p < 0.01). Conclusion: In summary, these data demonstrate that serum levels of osteopontin are elevated in nonalcoholic fatty liver disease and are a significant independent predictor of portal inflammation in this clinical entity. (C) 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.en_US
dc.description.sponsorshipInstitute of Gastroenterology, Marmara University, Istanbul, Turkeyen_US
dc.description.sponsorshipThis study was supported by grants from the Institute of Gastroenterology, Marmara University, Istanbul, Turkey.en_US
dc.identifier.doi10.1016/j.dld.2012.08.017
dc.identifier.endpage62en_US
dc.identifier.issn1590-8658
dc.identifier.issue1en_US
dc.identifier.pmid22995553
dc.identifier.scopus2-s2.0-84871607483
dc.identifier.scopusqualityQ1
dc.identifier.startpage58en_US
dc.identifier.urihttps://doi.org/10.1016/j.dld.2012.08.017
dc.identifier.urihttps://hdl.handle.net/11468/15335
dc.identifier.volume45en_US
dc.identifier.wosWOS:000315930000012
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofDigestive and Liver Disease
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiomarkeren_US
dc.subjectInflammationen_US
dc.subjectNonalcoholic Fatty Liver Diseaseen_US
dc.subjectOsteopontinen_US
dc.subjectPortal Inflammationen_US
dc.titleSerum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver diseaseen_US
dc.titleSerum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu